Growing Clinical Adoption With over 1,200 hospitals worldwide utilizing LungQ® for pulmonary disease assessment, Thirona demonstrates strong global acceptance and potential to expand further into hospitals seeking advanced AI tools for respiratory diagnostics.

Funding and Innovation Recent investments totaling over 11 million USD from European and private sources indicate active financial backing, enabling Thirona to accelerate product development and explore new applications in thoracic imaging.

Focus on Pulmonary Diseases Thirona's specialized AI solutions target lung conditions, offering opportunities to partner with hospitals, research institutions, and pharmaceutical companies interested in improving respiratory disease diagnosis and treatment.

Expanding AI Capabilities The launch of LungQ AVX and development of algorithms for chest X-ray and CT scan analysis for COVID-19 demonstrates continuous innovation, opening doors for opportunities in emerging imaging biomarkers and integrated diagnostic platforms.

Strategic Collaborations Thirona’s active participation in industry conferences and collaborations with research institutions suggest strong avenues for forming strategic partnerships to enhance product credibility and unlock additional sales channels in medical imaging.